论文部分内容阅读
目的：探讨国产尿激酶与进口链激酶溶栓治疗急性心肌梗死（ＡＭＩ）的疗效和副作用。方法：ＡＭＩ病人９７例，分为２组。尿激酶组５４例（男性３５例，女性１９例；年龄６２ａ±ｓ８ａ）给尿激酶１．５ＭＵ，链激酶组４３例（男性２８例，女性１５例；年龄６３ａ±９ａ）给链激酶１．５ＭＵ；２药均溶于５％葡萄糖注射液１５０ｍＬ中于３０ｍｉｎ内静脉滴注×１次；２组常规治疗相同。结果：尿激酶组与链激酶组的血管开通率和死亡率比较，依次为６７％（３６／５４），７０％（３０／４３）和７％（４／５４），７％（３／４３），均Ｐ＞０．０５，链激酶组１例出现脑出血。结论：尿激酶治疗ＡＭＩ疗效与链激酶相似。
Objective: To investigate the curative effect and side effects of domestic urokinase and imported streptokinase in acute myocardial infarction (AMI). Methods: 97 AMI patients were divided into two groups. In the urokinase group, 54 patients (35 males, 19 females; age 62a ± s8a) gave 1.5MU of urokinase and 43 streptokinase groups (28 males and 15 females; age 63a ± 9a). 5MU; 2 drugs were dissolved in 5% glucose injection 150mL in 30min intravenous infusion × 1 times; 2 groups of conventional treatment the same. Results: The rates of blood vessel opening and mortality of urokinase group and streptokinase group were 67% (36/54), 70% (30/43), 7% (4/54), 7% (3/43 ), P> 0.05, 1 case of streptokinase brain hemorrhage. Conclusion: The efficacy of urokinase in treating AMI is similar to streptokinase.